{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T10:26:16Z","timestamp":1787135176718,"version":"build-2736575974"},"reference-count":132,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"AstraZeneca international"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:p>Biomarker testing is central to precision oncology, enabling effective use of targeted therapies in hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (mBC). Recommendations for current and future biomarker testing and diagnostic workflows were developed using a three-step approach: pre-meeting survey, descriptive analysis, and steering committee discussion. A panel of 14 experts from Latin America, Asia Pacific, the Middle East, and Africa developed recommendations using an expert opinion-based approach without a formal consensus methodology. Recommendations with &gt;90% agreement were considered panel recommendations. Some recommendations are expert-driven and not yet standard-of-care. High agreement was observed for biomarker testing at diagnosis for estrogen receptor (ER), progesterone receptor (PR), HER2, and BReast CAncer gene (BRCA)1\/2. For endocrine-resistant patients, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) testing is recommended at diagnosis; otherwise, during or after first-line treatment. AKT serine\/threonine kinase 1 (AKT1) and phosphatase and tensin homolog (PTEN) testing can occur either during first-line treatment or at progression, while estrogen receptor 1 (ESR1) testing is advised at progression. Tumor tissue (preferably from a re-biopsy) is the preferred sample for PIK3CA, AKT1, and PTEN testing; if unavailable, primary tissue or circulating tumor DNA (ctDNA) may be considered. Blood is recommended for germline BRCA1\/2 or PALB2 testing, while ctDNA is preferred for ESR1 detection. Next-generation sequencing (NGS) is the preferred method for most biomarkers, with polymerase chain reaction as an alternative where NGS is unavailable; PTEN may also be assessed using immunohistochemistry. Above 90% of experts proposed future biomarker testing at diagnosis for ER, PR, HER2, germline BRCA1\/2, PALB2, PIK3CA, AKT1, PTEN, mismatch repair, microsatellite instability, tumor mutational burden, and neurotrophic tyrosine receptor kinase in all patients with HR+, HER2-negative mBC. This article offers a practical guide for biomarker testing in HR+, HER2-negative mBC.<\/jats:p>","DOI":"10.1177\/17588359261472325","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T05:21:29Z","timestamp":1786944089000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Biomarker testing in advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2 negative breast cancer: expert recommendations"],"prefix":"10.1177","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4715-1415","authenticated-orcid":false,"given":"Tom\u00e1s","family":"Reinert","sequence":"first","affiliation":[{"name":"Hospital Nora Teixeira\/Santa Casa de Porto Alegre, Porto Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed S.","family":"Alshehri","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia"},{"name":"Internal Medicine and Medical Oncology, Princess Noorah Oncology Center, Jeddah, Saudi Arabia"},{"name":"King Abdulaziz Medical City, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Shafik","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Faculty of Medicine, Ain Shams University, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Hung","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, and Quality Control and Infection Control Center, National Taiwan University, Cancer Center Branch, Taipei City, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Gomez Abuin","sequence":"additional","affiliation":[{"name":"Breast\/GYN Medical Oncology Unit, Oncology Department and Research Department, Hospital Aleman, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyungyub","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Pathology, Asan Medical Center, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1580-7224","authenticated-orcid":false,"given":"Kyung Hae","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mora","family":"Amat","sequence":"additional","affiliation":[{"name":"Pathological Anatomy Service, Instituto Alexander Fleming, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirmala","family":"Pathmanathan","sequence":"additional","affiliation":[{"name":"Westmead Breast Cancer Institute, Sydney, Australia"},{"name":"The University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel G. W.","family":"Ow","sequence":"additional","affiliation":[{"name":"Department of Hematology\u2013Oncology, National University Cancer Institute, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Rivera-Rivera","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Center, American British Cowdray Medical Center, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyam","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sir Ganga Ram Hospital, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Luen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Peter MacCallum Cancer Center, Melbourne, Australia"},{"name":"Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy Kwang","family":"Yong Tay","sequence":"additional","affiliation":[{"name":"Department of Anatomical Pathology, Singapore General Hospital, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,16]]},"reference":[{"key":"e_1_3_5_2_2","unstructured":"Global Cancer Observatory: Cancer Today. International agency for research on cancer https:\/\/gco.iarc.who.int\/today\/ (accessed 26 February 2025)."},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.01.040"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2022-0070-RA"},{"key":"e_1_3_5_5_2","article-title":"Clinical implications of the intrinsic molecular subtypes of breast cancer","volume":"24","author":"Prat A","year":"2015","unstructured":"Prat A, Pineda E, Adamo B, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast 2015; 24: S26\u2013S35.","journal-title":"Breast"},{"key":"e_1_3_5_6_2","unstructured":"Cancer Protocol Templates. College of American Pathologists https:\/\/www.cap.org\/protocols-and-guidelines\/cancer-reporting-tools\/cancer-protocol-templates (accessed 8 July 2025)."},{"key":"e_1_3_5_7_2","unstructured":"National Cancer Institute. Female breast cancer subtypes\u2014cancer Stat Facts. SEER https:\/\/seer.cancer.gov\/statfacts\/html\/breast-subtypes.html (accessed 26 February 2025)."},{"key":"e_1_3_5_8_2","unstructured":"American Cancer Society. Breast cancer facts & figures 2022\u20132024 https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/breast-cancer-facts-and-figures\/2022-2024-breast-cancer-fact-figures-acs.pdf (2022 accessed 26 February 2025)."},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251353623"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0264"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1677\/erc.1.00946"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3920"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2019.08.011"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.4048\/jbc.2022.25.e43"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-017-4160-5"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091401"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.3390\/genes14071364"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.1971"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01394-w"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214131"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.011"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404625"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706450"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.2098"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00338"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410858"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502929"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2505725"},{"key":"e_1_3_5_29_2","article-title":"Leveraging molecular diagnostic technologies to close the global cancer pathology gap","volume":"8","author":"Erfani P","year":"2022","unstructured":"Erfani P, Bates M, Garcia-Gonzalez P, et al. Leveraging molecular diagnostic technologies to close the global cancer pathology gap. JCO Glob Oncol 2022; 8: e2200182.","journal-title":"JCO Glob Oncol"},{"key":"e_1_3_5_30_2","unstructured":"NCCN\u00ae. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae ) for breast cancer V.1.2025. National Comprehensive Cancer Network Inc. NCCN.org (2025 accessed 25 February 2025)."},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01063"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00638"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00248"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.04.005"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.07.015"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2012.01.006"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15194689"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.07.005"},{"key":"e_1_3_5_40_2","first-page":"4252","article-title":"Genomic landscape of metastatic breast cancer identifies preferentially dysregulated pathways and targets","volume":"130","author":"Paul MR","year":"2020","unstructured":"Paul MR, Pan T-C, Pant DK, et al. Genomic landscape of metastatic breast cancer identifies preferentially dysregulated pathways and targets. J Clin Invest 2020; 130: 4252\u20134265.","journal-title":"J Clin Invest"},{"key":"e_1_3_5_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature09807"},{"key":"e_1_3_5_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-019-0507-7"},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS18-GS1-08"},{"key":"e_1_3_5_44_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1056-z"},{"key":"e_1_3_5_45_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002201"},{"key":"e_1_3_5_46_2","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3039"},{"key":"e_1_3_5_47_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143517"},{"key":"e_1_3_5_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2014.03.004"},{"key":"e_1_3_5_49_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02852-y"},{"key":"e_1_3_5_50_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.0891"},{"key":"e_1_3_5_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00284-4"},{"key":"e_1_3_5_52_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02086"},{"key":"e_1_3_5_53_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3573"},{"key":"e_1_3_5_54_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-011-1601-4"},{"key":"e_1_3_5_55_2","unstructured":"SABCS 2024: prevalence of PIK3CA\/AKT1\/PTEN and other genomic alterations in primary and recurrent tumor tissue: exploratory analysis from the phase 3 CAPItello-291 clinical trial https:\/\/clin.larvol.com\/abstract-detail\/SABCS%202024\/73369288 (2024 accessed 16 April 2025)."},{"key":"e_1_3_5_56_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01345-z"},{"key":"e_1_3_5_57_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1372947"},{"key":"e_1_3_5_58_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.8272"},{"key":"e_1_3_5_59_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-6854"},{"key":"e_1_3_5_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.08.008"},{"key":"e_1_3_5_61_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3276"},{"key":"e_1_3_5_62_2","article-title":"Comparison of PIK3CA mutation prevalence in breast cancer across predicted ancestry populations","volume":"6","author":"Chen JW","year":"2022","unstructured":"Chen JW, Murugesan K, Newberg JY, et al. Comparison of PIK3CA mutation prevalence in breast cancer across predicted ancestry populations. JCO Precis Oncol 2022; 6: e2200341.","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_5_63_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-1390"},{"key":"e_1_3_5_64_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2332"},{"key":"e_1_3_5_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2015.09.003"},{"key":"e_1_3_5_66_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac7551"},{"key":"e_1_3_5_67_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.1010"},{"key":"e_1_3_5_68_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.3519"},{"key":"e_1_3_5_69_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS20-PS18-15"},{"key":"e_1_3_5_70_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0224"},{"key":"e_1_3_5_71_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.1279"},{"key":"e_1_3_5_72_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01349-9"},{"key":"e_1_3_5_73_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS22-P5-03-14"},{"key":"e_1_3_5_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.550"},{"key":"e_1_3_5_75_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.1074"},{"key":"e_1_3_5_76_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-024-07376-w"},{"key":"e_1_3_5_77_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e13068"},{"key":"e_1_3_5_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2020.03.002"},{"key":"e_1_3_5_79_2","doi-asserted-by":"publisher","DOI":"10.1159\/000525092"},{"key":"e_1_3_5_80_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.19323"},{"key":"e_1_3_5_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.11.038"},{"key":"e_1_3_5_82_2","doi-asserted-by":"publisher","DOI":"10.3390\/genes12020285"},{"key":"e_1_3_5_83_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13193-022-01631-6"},{"key":"e_1_3_5_84_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaa201"},{"key":"e_1_3_5_85_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004975"},{"key":"e_1_3_5_86_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-10078-5"},{"key":"e_1_3_5_87_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02112"},{"key":"e_1_3_5_88_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802905"},{"key":"e_1_3_5_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.01.031"},{"key":"e_1_3_5_90_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.301"},{"key":"e_1_3_5_91_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02151"},{"key":"e_1_3_5_92_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400382"},{"key":"e_1_3_5_93_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00439-1"},{"key":"e_1_3_5_94_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2501796"},{"key":"e_1_3_5_95_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS23-PS17-03"},{"key":"e_1_3_5_96_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00387-5"},{"key":"e_1_3_5_97_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2019.03.008"},{"key":"e_1_3_5_98_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30691-6"},{"key":"e_1_3_5_99_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714448"},{"key":"e_1_3_5_100_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-31055-3"},{"key":"e_1_3_5_101_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.semdp.2022.06.015"},{"key":"e_1_3_5_102_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02923"},{"key":"e_1_3_5_103_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02105"},{"key":"e_1_3_5_104_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00673-9"},{"key":"e_1_3_5_105_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00568-1"},{"key":"e_1_3_5_106_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx273"},{"key":"e_1_3_5_107_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.09.019"},{"key":"e_1_3_5_108_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2010-0059"},{"key":"e_1_3_5_109_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS21-GS4-08"},{"key":"e_1_3_5_110_2","unstructured":"ESMO. HR-positive HER2-negative metastatic breast cancer https:\/\/www.esmo.org\/living-guidelines\/esmo-metastatic-breast-cancer-living-guideline\/hr-positive-her2-negative-metastatic-breast-cancer\/hr-positive-her2-negative-metastatic-breast-cancer\/de-novo-mbc-or-recurrence-12-months-after-the-end-of-adjuvant-et-et-sensitive-naive (accessed 18 April 2025)."},{"key":"e_1_3_5_111_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30444-7"},{"key":"e_1_3_5_112_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e15033"},{"key":"e_1_3_5_113_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2018.10.002"},{"key":"e_1_3_5_114_2","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221110162"},{"key":"e_1_3_5_115_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.366"},{"key":"e_1_3_5_116_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11579"},{"key":"e_1_3_5_117_2","article-title":"Genomic landscape of circulating tumor DNA in patients with hormone receptor-positive\/human epidermal growth factor receptor-2-negative metastatic breast cancer treated with abemaciclib: data from the SCRUM-Japan Cancer Genome Screening Project","volume":"8","author":"Hattori M","year":"2024","unstructured":"Hattori M, Serelli-Lee V, Naito Y, et al. Genomic landscape of circulating tumor DNA in patients with hormone receptor-positive\/human epidermal growth factor receptor-2-negative metastatic breast cancer treated with abemaciclib: data from the SCRUM-Japan Cancer Genome Screening Project. JCO Precis Oncol 2024; 8: e2300647.","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_5_118_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS20-PS4-06"},{"key":"e_1_3_5_119_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01601-9"},{"key":"e_1_3_5_120_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34525"},{"key":"e_1_3_5_121_2","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12305"},{"key":"e_1_3_5_122_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.1459"},{"key":"e_1_3_5_123_2","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2023-0950-SA"},{"key":"e_1_3_5_124_2","unstructured":"SABCS 2024: Capivasertib-fulvestrant for patients w\/ HR-pos\/HER2-negative advanced breast cancer who had relapsed or progressed during or after aromatase inhibitor treatment: exploratory analysis of PTEN deficiency by IHC from phase III CAPItello-291 trial https:\/\/clin.larvol.com\/abstract-detail\/SABCS%202024\/73369291 (2024 accessed 17 April 2025)."},{"key":"e_1_3_5_125_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-01976-y"},{"key":"e_1_3_5_126_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1221773"},{"key":"e_1_3_5_127_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0943"},{"key":"e_1_3_5_128_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2023.101176"},{"key":"e_1_3_5_129_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlb.2024.100151"},{"key":"e_1_3_5_130_2","doi-asserted-by":"publisher","DOI":"10.1039\/D0LC00096E"},{"key":"e_1_3_5_131_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00555-1"},{"key":"e_1_3_5_132_2","unstructured":"World Health Organization. GBCI implementation framework assessing strengthening and scaling up services for the early detection and management of breast cancer."},{"key":"e_1_3_5_133_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.06.011"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359261472325","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359261472325","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359261472325","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T09:46:31Z","timestamp":1787132791000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359261472325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":132,"alternative-id":["10.1177\/17588359261472325"],"URL":"https:\/\/doi.org\/10.1177\/17588359261472325","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"article-number":"17588359261472325"}}